TransMedics Group, Inc. TMDX
At closeNov 6, 2026, 8:23 AM EST
Pre-market · Nov 6, 8:23 AM ET
- YTD
- -43.30%
- 1 year
- -44.81%
- Market cap
- 2.38B
- Revenue (ttm)
- 668.47M
- Profit margin
- 22.69%
- EPS (ttm)
- 3.86
- Shares out
- 34.56M
- P/E ratio
- 17.87
- Forward P/E
- 32.28
- YTD return
- -43.30%
- 1-year return
- -44.81%
- Volume
- 1.67M
- Avg volume
- 811.54K
- Open
- 72.49
- Previous close
- 72.76
- Day's range
- 67.33 – 73.61
- 52-week range
- 60.11 – 156.00
- Beta
- 2.10
- Analysts
- Buy
- Price target
- 98.73 (+43.1%)
- Earnings date
- Feb 23, 2027
5D +2.25 (+3.37%)
Key statistics
- Enterprise value
- 2.73B
- PEG ratio
- 0.58
- Price / sales
- 3.76
- Price / book
- 4.86
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 20.70%
- Free cash flow
- 44.50M
- Total cash
- 472.68M
- Total debt
- 867.72M
- Return on equity
- 36.29%
- Short % of float
- 39.37%
- 50-day average
- 80.57
- 200-day average
- 93.72
Analyst view
Consensus: buy
- Target (low)
- 65.00
- Target (mean)
- 98.73
- Target (high)
- 125.00
- Strong buy3
- Buy6
- Hold4
- Sell0
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate 0.2934.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | 0.474 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | 0.2976 | 0.51 | +0.21 | +71.37% |
| Aug 4, 2026 | Jun 30, 2026 | 0.4955 | 0.44 | -0.06 | -11.20% |
| May 5, 2026 | Mar 31, 2026 | 0.62 | 0.30 | -0.32 | -51.61% |
| Feb 24, 2026 | Dec 31, 2025 | 0.41 | 0.57 | +0.16 | +39.02% |
| Oct 29, 2025 | Sep 30, 2025 | 0.37 | 0.66 | +0.29 | +78.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 13, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 7, 2026 | Barclays | init | — | Overweight |
| Sep 8, 2026 | TD Cowen | reit | Buy | Buy |
| Aug 5, 2026 | UBS | main | Neutral | Neutral |
| Aug 5, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Aug 3, 2026 | Needham | main | Buy | Buy |
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- transmedics.com
News
TransMedics (TMDX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates 
TransMedics Group, Inc. (TMDX) Q3 2026 Earnings Call Transcript 
TransMedics Group Raises FY2026 Sales Guidance from $737.000M-$757.000M to $750.000M-$760.000M vs $743.798M Est 
12 Health Care Stocks Moving In Thursday's After-Market Session - TransMedics Gr Q3 Adj. EPS $0.51 Beats $0.29 Estimate, Sales $203.005M Beat $177.584M Estimate
Reasons to Retain TransMedics Stock in Your Portfolio for Now 
What Analyst Projections for Key Metrics Reveal About TransMedics (TMDX) Q3 Earnings 
TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law 
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 
Canaccord Genuity Maintains Buy on TransMedics Group, Lowers Price Target to $94
Your note
Sign in to keep a note on TMDX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CECERE GIOVANNI | Officer | Stock Award(Grant) | Feb 17, 2026 | 19,057 |
| CORCORAN NICHOLAS | Officer | Stock Award(Grant) | Jul 9, 2026 | 41,558 |
| FORSYTH MATTHEW S | General Counsel | Stock Award(Grant) | May 18, 2026 | 15,409 |
| GUNDERSON THOMAS JAMES | Director | Sale | Jun 14, 2026 | 16,642 |
| HASSANEIN WALEED H | Chief Executive Officer | Stock Award(Grant) | Jul 9, 2026 | 666,102 |
| HERNANDEZ GERARDO | Chief Financial Officer | Stock Award(Grant) | Jul 9, 2026 | 31,935 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.19% | 5,596,549 | 407.18M | Jun 29, 2026 |
| FMR, LLC | 14.85% | 5,133,328 | 373.48M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.60% | 1,933,989 | 140.71M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.33% | 1,497,600 | 108.96M | Jun 29, 2026 |
| State Street Corporation | 4.11% | 1,420,421 | 103.34M | Jun 29, 2026 |
| Nomura Asset Management International Inc | 2.63% | 910,495 | 66.24M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.97% | 2,064,603 | 150.21M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 1,038,890 | 75.58M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.56% | 885,083 | 64.39M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.18% | 752,168 | 54.72M | Jun 29, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 2.10% | 726,130 | 52.83M | Jul 30, 2026 |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 1.79% | 617,377 | 44.92M | Aug 30, 2026 |